Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29394454 | 0.88 | HCAR3 (0.36) | HCAR3AOC3LMNACYP1A2CYP3A4 | |
| SCHEMBL2791067 | 0.83 | DGAT1 (0.42) | HCAR3LMNACYP1A2CYP3A4MAOA | |
| SCHEMBL8992767 | 0.83 | LMNA (0.42) | HCAR3LMNACYP1A2CYP3A4MAOA | |
| SCHEMBL477388 | 0.81 | HCAR3 (0.38) | HCAR3AOC3CA12CA1CA2 | |
| SCHEMBL2792080 | 0.81 | CA12 (0.36) | HCAR3SYKAOC3CYP1A2CA12 | |
| SCHEMBL4023870 | 0.80 | HCAR3 (0.39) | HCAR3SYKHDAC1TDP1ALDH1A1 | |
| SCHEMBL19418024 | 0.79 | CA12 (0.35) | HCAR3AOC3CA12CA1CA2 | |
| SCHEMBL2793256 | 0.78 | USP30 (0.44) | SYK | |
| SCHEMBL2790896 | 0.75 | HCAR3 (0.41) | HCAR3AOC3CA12CA1CA2 | |
| SCHEMBL15986962 | 0.75 | HRH3 (0.43) | AOC3LMNACYP1A2CYP3A4CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963313-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | MADRIGAL PHARMACEUTICALS INC (US) | 2012-11-14 | — | — | EP | claimed |
| EP-1963313-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-03 | — | — | EP | claimed |
| WO-2007060140-A2 | INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE (DGAT) | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | claimed |
| EP-1963313-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | MADRIGAL PHARMACEUTICALS INC (US) | 2012-11-14 | — | — | EP | disclosed |
| EP-1963313-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | MADRIGAL PHARMACEUTICALS INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20100190979-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190979-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190979-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100168419-A1 | Diacylglycerol Acyltransferase Inhibitors | BOLIN DAVID ROBERT | 2010-07-01 | — | — | US | disclosed |
| US-20100168419-A1 | Diacylglycerol Acyltransferase Inhibitors | BOLIN DAVID ROBERT | 2010-07-01 | — | — | US | disclosed |
| US-20100168419-A1 | Diacylglycerol Acyltransferase Inhibitors | BOLIN DAVID ROBERT | 2010-07-01 | — | — | US | disclosed |
| US-7714126-B2 | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714126-B2 | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| CN-101316844-A | Inhibitors of diacylglycerol acyltransferase (DGAT) | HOFFMANN LA ROCHE (CH) | 2008-12-03 | — | — | CN | disclosed |
| EP-1963313-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007060140-A2 | INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE (DGAT) | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007060140-A2 | INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE (DGAT) | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | disclosed |
| US-20070123504-A1 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
| US-20070123504-A1 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
| US-20070123504-A1 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168419-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | HCAR3 3114/4885SYK 4010/4885AOC3 2072/4885 |
| US-20100190979-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT2, DGAT1, LCAT | HCAR3 3114/4885SYK 4010/4885AOC3 2072/4885 |
| US-20070123504-A1 | Diacylglycerol acyltransferase inhibitors | DGAT2, DGAT1, LCAT | HCAR3 3114/4885SYK 4010/4885AOC3 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.